National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 9) (PB 83 of 2019) (Cth)

PB 83 of 2019

National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 9)

National Health Act 1953

___________________________________________________________________________

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated  30 September 2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

_________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 9).

(2)This Instrument may also be cited as PB 83 of 2019.

1. Commencement

This Instrument commences on 1 October 2019.

1. Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

1. Schedule 1, omit entry for Methyldopa

1. Schedule 2

substitute::

Listed Drug	Form	Manner of Administration	Brand	Circumstances
Amoxicillin	Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL	Oral	Amoxil	Infection suspected or proven to be due to a susceptible organism The treatment must be for patients who require a liquid formulation and in whom the syrup formulations are unsuitable
Eprosartan	Tablet 400 mg (as mesilate)	Oral	Teveten	Adverse effects occurring with all of the base‑priced drugs. Drug interactions occurring with all of the base‑priced drugs. Drug interactions expected to occur with all of the base‑priced drugs. Transfer to a base‑priced drug would cause patient confusion resulting in problems with compliance.
Tablet 600 mg (as mesilate)	Oral	Teveten	Adverse effects occurring with all of the base‑priced drugs. Drug interactions occurring with all of the base‑priced drugs. Drug interactions expected to occur with all of the base‑priced drugs. Transfer to a base‑priced drug would cause patient confusion resulting in problems with compliance.
Naratriptan	Tablet 2.5 mg (as hydrochloride)	Oral	Naramig	Migraine attack The condition must have usually failed to respond to analgesics in the past; AND Patient must be one in whom transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance.
Migraine attack The condition must have usually failed to respond to analgesics in the past; AND Patient must be one in whom transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences.
Migraine attack The condition must have usually failed to respond to analgesics in the past; AND Patient must be one in whom adverse events have occurred with other suitable PBS-listed drugs.
Migraine attack The condition must have usually failed to respond to analgesics in the past; AND Patient must be one in whom drug interactions are expected to occur with other suitable PBS-listed drugs.
Migraine attack The condition must have usually failed to respond to analgesics in the past; AND Patient must be one in whom drug interactions have occurred with other suitable PBS-listed drugs.